Literature DB >> 3029227

A specific assay measuring binding of 125I-Gp 120 from HIV to T4+/CD4+ cells.

K Lundin, A Nygren, L O Arthur, W G Robey, B Morein, U Ramstedt, M Gidlund, H Wigzell.   

Abstract

The HIV (HTLV-III) envelope glycoprotein, Gp120, was isolated from virus-infected tissue culture cells using affinity chromatography. A radioimmunoassay was developed to determine the degree of iodinated Gp120 to target CD4+ (T4+) cells. 125I-Gp120 could be shown to selectively bind to CD4+ cells only. The Gp120 remained bound to these cells after repeated washes. Monoclonal anti-CD4 antibodies block the binding of Gp120 to CD4+ cells. Monoclonal antibodies to other cell surface components do not interfere with 125I-Gp120 binding. All IgG antibodies from HIV seropositive donors tested block 125I-Gp120 binding, though with variable titers. We believe that this assay provides further proof for the use of CD4 (T4) as a component of the receptor for HIV. It represents a safe, objective and sensitive method for the analysis of Gp120-CD4 interactions, as well as the potential of antibodies to interfere with this binding.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3029227     DOI: 10.1016/0022-1759(87)90110-4

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  10 in total

1.  Cystein 402 of HIV gp 120 is essential for CD4-binding and resistance of gp 120 to intracellular degradation.

Authors:  A Hemming; A Bolmstedt; P Flodby; L Lundberg; M Gidlund; H Wigzell; S Olofsson
Journal:  Arch Virol       Date:  1989       Impact factor: 2.574

2.  95- and 25-kDa fragments of the human immunodeficiency virus envelope glycoprotein gp120 bind to the CD4 receptor.

Authors:  A Nygren; T Bergman; T Matthews; H Jörnvall; H Wigzell
Journal:  Proc Natl Acad Sci U S A       Date:  1988-09       Impact factor: 11.205

3.  A soluble recombinant polypeptide comprising the amino-terminal half of the extracellular region of the CD4 molecule contains an active binding site for human immunodeficiency virus.

Authors:  E A Berger; T R Fuerst; B Moss
Journal:  Proc Natl Acad Sci U S A       Date:  1988-04       Impact factor: 11.205

4.  Binding region for human immunodeficiency virus (HIV) and epitopes for HIV-blocking monoclonal antibodies of the CD4 molecule defined by site-directed mutagenesis.

Authors:  T Mizukami; T R Fuerst; E A Berger; B Moss
Journal:  Proc Natl Acad Sci U S A       Date:  1988-12       Impact factor: 11.205

5.  Differences in affinity of anti-CD4 monoclonal antibodies predict their effects on syncytium induction by human immunodeficiency virus.

Authors:  D Wilks; L Walker; J O'Brien; J Habeshaw; A Dalgleish
Journal:  Immunology       Date:  1990-09       Impact factor: 7.397

6.  Production and characterization of a fragment containing the HIV-gp120 binding region of CD4 using a bovine papilloma virus (BPV) vector.

Authors:  M Gidlund; M Sydow; A Stenbeck; P Flodby; H Fossum; S Matsuda; K Lundin; H Wigzell; P Lind
Journal:  Arch Virol       Date:  1990       Impact factor: 2.574

7.  Human immunodeficiency virus glycoprotein (gp120) induction of monocyte arachidonic acid metabolites and interleukin 1.

Authors:  L M Wahl; M L Corcoran; S W Pyle; L O Arthur; A Harel-Bellan; W L Farrar
Journal:  Proc Natl Acad Sci U S A       Date:  1989-01       Impact factor: 11.205

8.  Characterization of in vitro inhibition of human immunodeficiency virus by purified recombinant CD4.

Authors:  R A Byrn; I Sekigawa; S M Chamow; J S Johnson; T J Gregory; D J Capon; J E Groopman
Journal:  J Virol       Date:  1989-10       Impact factor: 5.103

9.  Structural analysis of the human immunodeficiency virus-binding domain of CD4. Epitope mapping with site-directed mutants and anti-idiotypes.

Authors:  Q J Sattentau; J Arthos; K Deen; N Hanna; D Healey; P C Beverley; R Sweet; A Truneh
Journal:  J Exp Med       Date:  1989-10-01       Impact factor: 14.307

Review 10.  Pathophysiology of ocular surface squamous neoplasia.

Authors:  Stephen Gichuhi; Shin-ichi Ohnuma; Mandeep S Sagoo; Matthew J Burton
Journal:  Exp Eye Res       Date:  2014-10-18       Impact factor: 3.467

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.